First-line approval for the combined use of new and independent Pol inhibitor SIM0508 with Olaparib.

On August 20, Akeso Pharma Group's innovative anti-tumor drug company Akeso Zaiming announced that its self-developed anti-tumor candidate drug - DNA polymerase small molecule inhibitor SIM0508 has been approved by the National Medical Products Administration to conduct clinical trials in the treatment of advanced solid tumors in combination with Olaparib.